Compare Immunovant Inc. Common Stock (IMVT) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: Immunovant Inc. Common Stock is far larger — about 3× Under Armour Inc Class A's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Under Armour Inc Class A for 18 Days on average.
| IMVT | UA | |
|---|---|---|
Market Cap | $6.25B | $2.07B |
Volume | 1,755,411 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $7.88 |
52-Week Low | $17.03 | $3.96 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $5.35B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UA) trades at $4.70, down 0.42% with a bearish technical outlook despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenue trends, though it maintains a reasonable P/S ratio of 0.41. Recent quarterly results show mixed performance with two beats and one miss, while cash flow remains negative across all categories.
The stock presents high risk with deteriorating fundamentals and negative profitability metrics. While analyst sentiment leans slightly positive with 41% buy ratings, the company's revenue declines and negative cash flow position create substantial headwinds. Investment opportunity exists only for those betting on a successful turnaround strategy execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
